Can cholesterol drug or milk thistle tame sepsis?
NCT ID NCT07572552
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two drugs—fenofibrate (a cholesterol medicine) and silymarin (from milk thistle)—in 66 adults with sepsis. The goal is to see if either can reduce harmful inflammation and organ damage better than standard care alone. The trial is not yet recruiting and is in Phase 2, meaning it's still early and small.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fenofibrate and silymarin
What this could lead to
If it works, this could point toward a new way to control inflammation and organ damage in sepsis patients.
What could go wrong
This is a small, early-phase trial with only 66 participants. The results may not apply to all sepsis patients, and neither drug may prove better than standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEPSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.